A more precise diagnosis by means of amyloid PET contributes to delayed institutionalization, lower mortality, and reduced care costs in a tertiary memory clinic setting.

Abstract

We aim to study the effect of a more precise diagnosis, by means of amyloid positron emission tomography (PET), on institutionalization, mortality, and health-care costs. Between October 27, 2014 and December 31, 2016, we offered amyloid PET to all patients as part of their diagnostic work-up. Patients who accepted to undergo amyloid PET (n=449) were propensity score matched with patients without amyloid PET (n=571, i.e., no PET). Matched groups (both n=444) were compared on rate of institutionalization, mortality, and health-care costs in the years after diagnosis. Amyloid PET patients had a lower risk of institutionalization (10% [n=45] vs. 21% [n=92]; hazard ratio [HR]=0.48 [0.33-0.70]) and mortality rate (11% [n=49] vs. 18% [n=81]; HR=0.51 [0.36-0.73]) and lower health-care costs in the years after diagnosis compared to matched no-PET patients (β=-4573.49 [-6524.76 to -2523.74], P-value<0.001). A more precise diagnosis in tertiary memory clinic patients positively influenced the endpoints of institutionalization, death, and health-care costs.